17
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3458 |
EED226
|
Histone Methyltransferase | Chromatin/Epigenetic |
EED226 是多梳抑制复合物 2 抑制剂,是一种有效的、选择性的、可口服的胚胎外胚层发育 (EED) 抑制剂,IC50 为 22 nM,具有强抗肿瘤活性。当 H3K27me0 肽用作体外酶法测定的底物时,它抑制 PRC2的 IC50为 23.4 nM。 | |||
T7305 |
JQEZ5
|
Histone Methyltransferase | Chromatin/Epigenetic |
JQEZ5 是一种选择性EZH2赖氨酸甲基转移酶抑制剂,具有抗肿瘤作用。它以 SAM 竞争性方式抑制PRC2的酶功能,IC50为 80 nM。 | |||
T7378 |
BRD9539
|
Histone Methyltransferase | Chromatin/Epigenetic |
BRD9539 是一种组蛋白甲基转移酶G9a 抑制剂,IC50为 6.3 μM,还抑制PRC2活性。 | |||
T13954 |
UNC6852
|
Histone Methyltransferase; Ligands for Target Protein for PROTAC | Chromatin/Epigenetic; PROTAC |
UNC6852 包含一个 EED 配体 (IC50 = 247 nM) 和一个 von Hippel-Lindau 配体,是一种基于 PROTAC 的特异性多梳抑制复合物 2 (PRC2) 降解剂。 | |||
T1788 |
Tazemetostat
E-7438,EPZ6438 |
Histone Methyltransferase | Chromatin/Epigenetic |
Tazemetostat (EPZ6438) 是一种组蛋白甲基转移酶 EZH2 抑制剂 (IC50=11 nM),具有口服活性、选择性和 SAM 竞争性。Tazemetostat 具有抗肿瘤活性,可以用于治疗上皮样肉瘤/滤泡性淋巴瘤。 | |||
T17002 |
Tazemetostat hydrobromide
E-7438 hydrobromide,氢溴酸泰泽司他,EPZ-6438 hydrobromide |
Histone Methyltransferase | Chromatin/Epigenetic |
Tazemetostat hydrobromide (E-7438 hydrobromide) 是口服的EZH2选择性抑制剂。它抑制含有 PRC2 复合体的野生型 EZH2 的活性,Ki 为 2.5 nM。它还抑制 EZH1,IC50为 392 nM。 | |||
T10205 |
A-395
|
Histone Methyltransferase | Chromatin/Epigenetic |
A-395 是一种多梳抑制复合物 2 (PRC2) 蛋白质-蛋白质相互作用的拮抗剂,可有效抑制三聚体 PRC2 复合物 (EZH2-EED-SUZ12),IC50为 18 nM。 | |||
T60044 |
SPEN-IN-1
|
Others | Others |
SPEN-IN-1 结合抑制组蛋白 H3K27 三甲基化并阻断 X 染色体失活的起始。 SPEN-IN-1 结合减少了 RepA 的构象空间并取代了同源相互作用的蛋白质因子,包括 PRC2 和 SPEN。 | |||
T29231 |
ZLD1039
ZLD-1039,ZLD 1039 |
Histone Methyltransferase | Chromatin/Epigenetic |
ZLD1039 是一种口服有效的、高选择性 EZH2 抑制剂。ZLD1039 高效抑制 EZH2 野生型及 Y641F 和 A677G 突变型,IC50 分别为 5.6、15 和 4.0 nM。ZLD1039 抑制乳腺肿瘤的生长和转移。 | |||
T61825 | EED ligand 1 | ||
EED ligand 1 is a highly versatile, potent, and effective inhibitor that specifically targets the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase. | |||
T17931 |
EED226-COOH
|
Others | Others |
EED226-COOH, derived from EED226, serves as a ligand targeting the EED protein for PROTAC applications. It attaches to a VHL ligand through a linker, culminating in the formation of UNC6852, which specifically degrades PRC2[1]. | |||
T12554 | PROTAC EED degrader-2 | Others | Others |
PROTAC EED degrader-2 is a PROTAC targeting EED (pKD of 9.27),is a inhibitor of polycomb repressive complex 2 (PRC2) with pIC50 of 8.11. | |||
T73134 | EZH2-IN-14 | ||
EZH2-IN-14为一种选择性EZH2(Histone Methyltransferase)抑制剂,具IC50值12 nM。该化合物通过抑制EZH2/PRC2的甲基转移酶活性(减少H3K27me3),显著抑制其功能。相比高度同源的H3K27甲基转移酶EZH1,EZH2-IN-14对EZH2的选择性提高200倍以上。 | |||
T15240 |
Tazemetostat trihydrochloride
EPZ-6438 trihydrochloride,E-7438 trihydrochloride |
Histone Methyltransferase | Chromatin/Epigenetic |
Tazemetostat trihydrochloride is a selective and orally available inhibitor of EZH2 (IC50: 4 nM for rat EZH2). It inhibits the activity of human PRC2-containing wild-type EZH2 (Ki: 2.5 nM). It inhibits EZH2 (IC50s: 11 and 16 nM in peptide assay and nucleo | |||
T17653 |
Boc-NH-C4-acid
Boc-5-氨基戊酸 |
Others; PROTAC Linker | Others; PROTAC |
Boc-NH-C4-acid 是一种属于 Alkyl/ether 类的 PROTAC linker,可用于 PROTAC1 的合成,并且可以降解 PRC2 中的 EED,EZH2,和 SUZ12。 | |||
T12553 |
PROTAC EED degrader-1
|
Others | Others |
PROTAC EED degrader-1 is a PROTAC targeting EED (pKD = 9.02), is a inhibitor of polycomb repressive complex 2 (PRC2) with pIC50 of 8.17. | |||
T69771 |
MS-177
|
||
MS177 is an effective and fast-acting EZH2 degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC50): 12 nM). MS177 effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN2646 |
16-Hydroxycleroda-3,13-dien-15,16-olide
|
Autophagy | Autophagy |
16-Hydroxycleroda-3,13-dien-15,16-olide, and prodigiosin are presented as candidates for autophagy inducers that can trigger cell death in a supplement or alternative medicine for cancer therapy. 16-Hydroxycleroda-3,13-dien-15,16-olide regulates the expre |